Institutional Investor Sentiment About Harvard Bioscience Inc (NASDAQ:HBIO) Up

April 19, 2018 - By Peter Erickson

Harvard Bioscience, Inc. (NASDAQ:HBIO) Logo

Sentiment for Harvard Bioscience Inc (NASDAQ:HBIO)

Harvard Bioscience Inc (NASDAQ:HBIO) institutional sentiment increased to 1.32 in Q4 2017. Its up 0.41, from 0.91 in 2017Q3. The ratio has increased, as 25 investment professionals increased and opened new holdings, while 19 reduced and sold their equity positions in Harvard Bioscience Inc. The investment professionals in our partner’s database now have: 22.13 million shares, up from 21.49 million shares in 2017Q3. Also, the number of investment professionals holding Harvard Bioscience Inc in their top 10 holdings was flat from 2 to 2 for the same number . Sold All: 3 Reduced: 16 Increased: 17 New Position: 8.

Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company has market cap of $199.38 million. The firm offers cell and animal physiology products, such as syringe pump and peristaltic pump products, as well as a range of instruments and accessories, including surgical products, infusion systems, microdialysis instruments, behavior research systems, and isolated organ and tissue bath systems, as well as in vivo and in vitro electrophysiology recording, stimulation, and analysis systems for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, InBreath Bioreactor, MCS, TBSI, and HEKA brands. It currently has negative earnings. It also provides products for molecular biology labs comprising pipettes and pipette tips, gloves, gel electrophoresis equipment and reagents, autoradiography films, thermal cycler accessories and reagents, sample preparation columns, tissue culture products, and general lab equipment and consumables under the Denville Scientific and other brands.

The stock decreased 4.27% or $0.25 during the last trading session, reaching $5.6. About 53,628 shares traded. Harvard Bioscience, Inc. (NASDAQ:HBIO) has risen 87.27% since April 19, 2017 and is uptrending. It has outperformed by 75.72% the S&P500.

Analysts await Harvard Bioscience, Inc. (NASDAQ:HBIO) to report earnings on April, 26. HBIO’s profit will be $356,032 for 140.00 P/E if the $0.01 EPS becomes a reality. After $0.04 actual EPS reported by Harvard Bioscience, Inc. for the previous quarter, Wall Street now forecasts -75.00 % negative EPS growth.

Glacier Peak Capital Llc holds 6.38% of its portfolio in Harvard Bioscience, Inc. for 1.33 million shares. First Light Asset Management Llc owns 4.64 million shares or 4.2% of their US portfolio. Moreover, Bard Associates Inc has 0.55% invested in the company for 347,372 shares. The Wisconsin-based Heartland Advisors Inc has invested 0.36% in the stock. Granahan Investment Management Inc Ma, a Massachusetts-based fund reported 935,717 shares.#img1#

Since January 1, 0001, it had 0 insider buys, and 3 sales for $1.00 million activity.

Harvard Bioscience, Inc. (NASDAQ:HBIO) Ratings Coverage

Ratings analysis reveals 100% of Harvard Bioscience’s analysts are positive. Out of 2 Wall Street analysts rating Harvard Bioscience, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $8.0 while the high is $1000. The stock’s average target of $9 is 60.71% above today’s ($5.6) share price. HBIO was included in 2 notes of analysts from January 24, 2018.

Harvard Bioscience, Inc. (NASDAQ:HBIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.